Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
General Rheumatology
•
Biosimilars
Do we need to be concerned about immunogenicity and effectiveness of biosimilars in patients who may need to switch multiple times due to insurance reasons?
Related Questions
How do you interpret small joint effusions seen on ultrasound without power doppler signal in the setting of compatible inflammatory symptoms (i.e morning stiffness)?
How do you approach isolated hip arthropathy with chondral loss in the setting of a moderately positive rheumatoid factor?
Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?
How do you manage a patient with cervical cancer who has FDG uptake in bilateral ischial tuberosities with lytic areas on CT correlate, and also has a history suspicious for untreated polymyalgia rheumatica with chronic symptoms in the same anatomic locations?
Would you feel comfortable adding benlysta to patient already taking both mycophenolate and tacrolimus (and hydroxychloroquine) who still has some evidence of active lupus nephritis?
Do you routinely obtain urine pregnancy tests in patients on immunosuppression who use only a single method of contraception?
How do you manage a patient with severe RA or SLE that worsens after stopping immunosuppressants due to having chronic foot ulceration?
How do you approach initiation/continuation of biologics if there is a suspicious pulmonary nodule that requires close interval imaging (i.e every 3 or 6 months)?
Do you consider IgM or IgA levels in addition to IgG levels when planning further doses of rituximab?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
